| Autor: |
Jennifer A. Rymer, Eileen Fonseca, Durgesh D. Bhandary, Deepa Kumar, Naeem D. Khan, Tracy Y. Wang |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 1 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.119.016215 |
| Popis: |
Background Evidence‐based medication adherence rates after a myocardial infarction are low. We hypothesized that 90‐day prescriptions are underused and may lead to higher evidence‐based medication adherence compared with 30‐day fills. Methods and Results We examined patients with myocardial infarction treated with percutaneous coronary intervention between 2011 and 2015 in the National Cardiovascular Data Registry. Linking to Symphony Health pharmacy data, we described the prevalence of patients filling 30‐day versus 90‐day prescriptions of statins, β‐blockers, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and P2Y12 inhibitors after discharge. We compared 12‐month medication adherence rates by evidence‐based medication class and prescription days' supply and rates of medication switches and dosing changes. Among 353 259 patients with myocardial infarction treated with percutaneous coronary intervention, 90‐day evidence‐based medication fill rates were low: 13.0% (statins), 12.3% (β‐blockers), 14.6% (angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers), and 9.7% (P2Y12 inhibitors). Patients filling 90‐day prescriptions were more likely older (median 69 versus 62 years) with a history of prior myocardial infarction (25.0% versus 17.9%) or percutaneous coronary intervention (30.3% versus 19.5%; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text